Skip to main content
. 2021 Jun 11:10.4155/bio-2021-0065. doi: 10.2217/rme-2021-0025

Table 2. Trial group phases.

Trial type Trials analyzed Early Phase I Phase I Phase I/II Phase II Phase II/III Phase III Phase not specified
COVID-related trials 55 3 (5.5%) 8 (14.6%) 19 (34.6%) 19 (34.6%) 2 (3.6%) 1 (1.8%) 3 (5.6%)
Non-COVID control group (mean of three sets) 38.7 1.33 (3.4%) 10.7 (27.7%) 10.3 (26.6%) 7.33 (18.9%) 0.67 (1.7%) 3.7 (9.6%) 4.7 (12.1%)